Search Result

Results for "

FOXO

" in MedChemExpress (MCE) Product Catalog:

By Targets:	FOXO (7) 5-HT Receptor (1) Akt (7) AMPK (1) Amyloid-β (2) Apoptosis (11) Autophagy (5) Bacterial (1) CD276/B7-H3 (1) Cytochrome P450 (1) DAPK (1) Dopamine Receptor (1) EGFR (2) Endogenous Metabolite (5) Epigenetic Reader Domain (1) ERK (1) Glycosidase (1) HDAC (1) Histone Demethylase (1) Interleukin Related (2) Isocitrate Dehydrogenase (IDH) (1) Isotope-Labeled Compounds (1) MDM-2/p53 (2) Mitophagy (1) MMP (1) nAChR (1) NF-κB (1) NO Synthase (1) Nuclear Hormone Receptor 4A/NR4A (1) Organoid (2) p38 MAPK (1) PERK (1) Phosphatase (1) Phosphodiesterase (PDE) (2) PI3K (2) PINK1/Parkin (1) Potassium Channel (1) PPAR (1) Pyroptosis (1) Reactive Oxygen Species (ROS) (2) Reference Standards (3) Ribosomal S6 Kinase (RSK) (1) Sirtuin (1) Small Interfering RNA (siRNA) (12) Tau Protein (1) TNF Receptor (1) Xanthine Oxidase (1) YTHDF (1)
By Research Areas:	Cancer (22) Cardiovascular Disease (2) Endocrinology (1) Infection (1) Inflammation/Immunology (3) Metabolic Disease (14) Neurological Disease (8)
Oligonucleotides:	Nucleoside Analogs (1) Rat Pre-designed siRNA Sets (4) Mouse Pre-designed siRNA Sets (4) Human Pre-designed siRNA Sets (4) siRNAs (12)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: FOXO

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P4157

FOXO4-DRI	MDM-2/p53 Apoptosis	Metabolic Disease
FOXO4-DRI is a cell-permeable peptide antagonist that blocks the interaction of *FOXO4* and p53. FOXO4-DRI is a senolytic peptide that induces apoptosis of senescent cells .

HY-153617

FOXO1-IN-3 1 Publications Verification	FOXO	Metabolic Disease
FOXO1-IN-3 is a highly-selective and orally active *FOXO1* inhibitor. FOXO1-IN-3 reduces hepatic glucose production in mice. FOXO1-IN-3 improves insulin sensitivity and glucose control in db/db mice without causing weight gain .

HY-P4157A

FOXO4-DRI acetate	MDM-2/p53 Apoptosis	Metabolic Disease
FOXO4-DRI acetate is a cell-permeable peptide antagonist that blocks the interaction of *FOXO4* and p53. FOXO4-DRI acetate is a senolytic peptide that induces apoptosis of senescent cells .

HY-RS29036

Foxo6 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Foxo6 Rat Pre-designed siRNA Set A contains three designed siRNAs for Foxo6 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Foxo6 Rat Pre-designed siRNA Set A Foxo6 Rat Pre-designed siRNA Set A

HY-RS05070

FOXO3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FOXO3 Human Pre-designed siRNA Set A contains three designed siRNAs for FOXO3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FOXO3 Human Pre-designed siRNA Set A FOXO3 Human Pre-designed siRNA Set A

HY-RS05072

FOXO6 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FOXO6 Human Pre-designed siRNA Set A contains three designed siRNAs for FOXO6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FOXO6 Human Pre-designed siRNA Set A FOXO6 Human Pre-designed siRNA Set A

HY-RS22515

Foxo6 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Foxo6 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Foxo6 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Foxo6 Mouse Pre-designed siRNA Set A Foxo6 Mouse Pre-designed siRNA Set A

HY-RS16559

Foxo1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Foxo1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Foxo1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Foxo1 Mouse Pre-designed siRNA Set A Foxo1 Mouse Pre-designed siRNA Set A

HY-RS16632

Foxo3 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Foxo3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Foxo3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Foxo3 Mouse Pre-designed siRNA Set A Foxo3 Mouse Pre-designed siRNA Set A

HY-RS23067

Foxo3 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Foxo3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Foxo3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Foxo3 Rat Pre-designed siRNA Set A Foxo3 Rat Pre-designed siRNA Set A

HY-RS23681

Foxo4 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Foxo4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Foxo4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Foxo4 Rat Pre-designed siRNA Set A Foxo4 Rat Pre-designed siRNA Set A

HY-RS22991

Foxo1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Foxo1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Foxo1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Foxo1 Rat Pre-designed siRNA Set A Foxo1 Rat Pre-designed siRNA Set A

HY-RS05071

FOXO4 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FOXO4 Human Pre-designed siRNA Set A contains three designed siRNAs for FOXO4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FOXO4 Human Pre-designed siRNA Set A FOXO4 Human Pre-designed siRNA Set A

HY-RS17228

Foxo4 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Foxo4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Foxo4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Foxo4 Mouse Pre-designed siRNA Set A Foxo4 Mouse Pre-designed siRNA Set A

HY-RS05069

FOXO1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FOXO1 Human Pre-designed siRNA Set A contains three designed siRNAs for FOXO1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FOXO1 Human Pre-designed siRNA Set A FOXO1 Human Pre-designed siRNA Set A

HY-100596

AS1842856 Maximum Cited Publications 77 Publications Verification	Autophagy	Metabolic Disease
AS1842856, a specific *Foxo1* inhibitor (IC₅₀=30 nM), potently suppresses autophagy . AS1842856 reduces *Foxo1* activity and, to a lesser extent, inhibits *Foxo1* protein expression by simply binding to *Foxo1* .

HY-153347

JY-2 1 Publications Verification	FOXO	Metabolic Disease
JY-2 is a moderately selective and orally active Forkhead transcription factor forkhead box O1 (FoxO1) inhibitor that inhibits FoxO1 transcriptional activity with an IC₅₀ of 22 μM. JY-2 shows moderate inhibition against FoxO3a and FoxO4. JY-2 shows anti-diabetic activity .

HY-100596G

AS1842856	Autophagy	Metabolic Disease
AS1842856 (GMP) is AS1842856 (HY-100596) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AS1842856, a specific *Foxo1* inhibitor (IC₅₀=30 nM), potently suppresses autophagy . AS1842856 reduces *Foxo1* activity and, to a lesser extent, inhibits *Foxo1* protein expression by simply binding to *Foxo1* .

HY-N3542

Carpachromene	Glycosidase	Cancer
Carpachromene is a potent α-glucosidase enzyme inhibitor. Carpachromene ameliorates insulin resistance in HepG2 cells via modulating IR/IRS1/PI3k/Akt/GSK3/FoxO1 pathway .

HY-139348

PFI-90	Histone Demethylase Apoptosis	Cancer
PFI-90 is a selective inhibitor of histone demethylase (KDM3B) that inhibits *PAX3-FOXO1* action. PFI-90 induces apoptosis and myogenic differentiation, resulting in the cell death increased. PFI-90 has the potential for the antitumor activity. (patent WO2021101929A1).

HY-101035

LOM612 2 Publications Verification	FOXO	Cancer
LOM612 is a potent *FOXO* relocator, with an EC₅₀ value of 1.5 μM in U2fox RELOC cells .

HY-162050

8AQ−Cu−5Iu	Sirtuin	Neurological Disease
8AQ?Cu?5Iu is an activator of SIRT1. 8AQ?Cu?5Iu exhibits neuroprotective effects by modulating the *SIRT1/3-FOXO3a* signaling pathway. 8AQ?Cu?5Iu can used in study attenuating neurodegenerative diseases .

HY-B1152

Piperacetazine 1 Publications Verification	Dopamine Receptor CD276/B7-H3 FOXO	Neurological Disease Cancer
Piperacetazine is an orally active dopamine receptor antagonist and phenothiazine antipsychotic. Piperacetazine can directly bind to the *PAX3::FOXO1* fusion protein and inhibit its transcriptional activity. Piperacetazine also exhibits antitumor activity with an IC₅₀ of 7.627 μM against PANC-1 cells. Piperacetazine can be used for the research of diseases such as schizophrenia and pancreatic cancer and other tumors .

HY-111299

Psammaplysene A	Apoptosis	Cancer
Psammaplysene A, a brominated tyrosine derivative, can promote the nuclear localization of *FOXO1, leading to cell cycle arrest and apoptosis*, and can be used in cancer research .

HY-148509

PhosTAC5	Others	Cancer
PhosTAC5 is a phosphorylation targeting chimera (PhosTAC) molecule composed of a linker with fivePEG groups. PhosTAC5 induces dephosphorylation of PDCD4 and FOXO3a .

HY-123046

AS1708727 3 Publications Verification	Autophagy	Metabolic Disease Cancer
AS1708727 is an orally active *Foxo1* inhibitor, with EC₅₀ values of 0.33 μM and 0.59 μM for G6Pase and PEPCK, respectively .

HY-148508

PhosTAC3	Others	Cancer
PhosTAC3 is a phosphorylation targeting chimera (PhosTAC) molecule composed of a linker with three PEG groups. PhosTAC3 induces dephosphorylation of PDCD4 and FOXO3a .

HY-174806

Y040-7904	Mitophagy PINK1/Parkin Amyloid-β	Neurological Disease
Y040-7904 is a mitophagy activator. Y040-7904 enhances mitophagy by promoting mitochondria transport to autophagosomes and the fusion of autophagosomes with autolysosomes. Y040-7904 induces mitophagy through the SIRT1/FoxO3 pathway. Y040-7904 upregulates the levels of Parkin, PINK1, and LC3II/I. Y040-7904 reduces amyloid-β (Aβ) accumulation in both in vitro and in vivo models of Alzheimer’s disease.

HY-B1462

Chlorzoxazone 3 Publications Verification	Cytochrome P450 Potassium Channel FOXO Amyloid-β	Neurological Disease Inflammation/Immunology
Chlorzoxazone is a SK-type potassium channel activator. Chlorzoxazone modulates *FOXO3* phosphorylation and Aβ. Chlorzoxazone enhances immunosuppression, attenuates vasoconstriction, attenuates cognitive deficits, and improves experimental autoimmune encephalomyelitis .

HY-122959

Kihadanin B	Akt PPAR	Metabolic Disease
Kihadanin B is a citrus limonoid that can be purified from the peels of immature Citrus unshiu. Kihadanin B suppresses adipogenesis through repression of the *Akt-FOXO1-PPARγ* axis in 3T3-L1 adipocytes .

HY-P4790

Acetyl-Exenatide	PI3K Akt	Metabolic Disease
Acetyl-Exenatideyes is an acetylated derivative of Exenatide. Exenatide has the function similar to insulin, which can be used for research of type 2 diabetes. Exenatide can promote Th17 differentiation, inhibits Tregs differentiation, downregulates PI3K/Akt/FoxO1 phosphorylation .

HY-112056

DIM-C-pPhCO2Me 1 Publications Verification	Nuclear Hormone Receptor 4A/NR4A Apoptosis DAPK Isocitrate Dehydrogenase (IDH) PERK	Cancer
DIM-C-pPhCO2Me is a nuclear receptor 4A1 (NR4A1) antagonist. DIM-C-pPhCO2Me induces Apoptosis. DIM-C-pPhCO2Me decreases *PAX3-FOXO1A, N-Myc, Rassf4, MyoD1, Grem1, and DAPK1* proteins. DIM-C-pPhCO2Me decreases expression of TXNDC5 and IDH1, induces markers of ER stress (CHOP, ATF4 and p-PERK). DIM-C-pPhCO2Me inhibits renal cell carcinoma, breast cancer. DIM-C-pPhCO2Me can also be used in rhabdomyosarcoma research .

HY-142125

Broussochalcone A	Xanthine Oxidase Reactive Oxygen Species (ROS) Apoptosis	Inflammation/Immunology Cancer
Broussochalcone A is an antioxidant and an inhibitor of Xanthine Oxidase (IC₅₀=2.21 μM), with free radical scavenging activity. Broussochalcone A inhibits iron-induced lipid peroxidation and nitric oxide synthesis in lipopolysaccharide (LPS) -activated macrophages. Broussochalcone A also induces Apoptosis of human renal carcinoma cells by increasing ROS levels and activating FOXO3 signaling pathways .

HY-W011527

Xanthosine 3 Publications Verification	Endogenous Metabolite	Metabolic Disease
Xanthosine is a nucleoside derived from xanthine and ribose. Xanthosine activates the *AMPK/FoxO1/AKT/GSK3β* signaling cascade. Xanthosine promotes cell proliferation and regulates blood glucose metabolism. Xanthosine increases milk production in cows and goats. Xanthosine is used in mammary stem cell and type 2 diabetes research .

HY-145232

PhosTAC7 3 Publications Verification	Phosphatase Tau Protein	Neurological Disease Cancer
PhosTAC7 is a heterobifunctional molecule named as a Phosphorylation Targeting Chimera (PhosTAC). PhosTAC7 can dephosphorylate the PDCD4 protein, *FOXO3a* protein, and Tau protein by recruiting serine/threonine protein phosphatase 2A (PP2A). PhosTAC7 offers the advantage of selectively modulating the phosphorylation state of individual target proteins, making it a promising tool for research in cancer and tau protein-related neurodegenerative diseases .

HY-16558

Butein 5 Publications Verification 2’,3,4,4’-tetrahydroxy Chalcone	EGFR Autophagy Apoptosis Phosphodiesterase (PDE)	Cancer
Butein is a cAMP-specific PDE inhibitor with an IC₅₀ of 10.4 μM for PDE4 . Butein is a specific protein tyrosine kinase inhibitor with IC₅₀s of 16 and 65 μM for EGFR and p60 ^c-src in HepG2 cells . Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a . Butein is a SIRT1 activator (STAC).

HY-15186

Ipatasertib 50+ Cited Publications GDC-0068; RG7440	Organoid Akt Apoptosis	Cancer
Ipatasertib (GDC-0068) is an orally active, highly selective and ATP-competitive pan-Akt inhibitor with IC₅₀ values of 5, 18, 8 nM for Akt1/2/3, respectively. Ipatasertib synchronously activates FoxO3a and NF-κB through inhibition of Akt leading to p53-independent activation of PUMA. Ipatasertib also induces apoptosis in cancer cells and inhibits tumor growth in xenograft mouse models .

HY-15186C

Ipatasertib tosylate GDC-0068 tosylate; RG7440 tosylate	Organoid Akt Apoptosis	Cancer
Ipatasertib (GDC-0068) tosylate is an orally active, highly selective and ATP-competitive pan-Akt inhibitor with IC₅₀ values of 5, 18, 8 nM for Akt1/2/3, respectively. Ipatasertib tosylate synchronously activates FoxO3a and NF-κB through inhibition of Akt leading to p53-independent activation of PUMA. Ipatasertib tosylate also induces apoptosis in cancer cells and inhibits tumor growth in xenograft mouse models .

HY-103100

SB-699551 1 Publications Verification	5-HT Receptor Epigenetic Reader Domain Akt Ribosomal S6 Kinase (RSK) FOXO	Neurological Disease Cancer
SB-699551 is a potent and selective 5-HT5A antagonist with a K_i value of 5.1 μM. SB-699551 increases the phosphorylation levels of CREB and ATF1, and decreases the phosphorylation levels of AKT, PRAS40, P70S6K, *FOXO1, and S6RP*. SB-699551 improves drug-induced cognitive deficits. SB-699551 improves social withdrawal and forgetfulness. SB-699551 inhibits breast cancer.

HY-W011527R

Xanthosine (Standard)	Reference Standards Endogenous Metabolite	Others
Xanthosine (Standard) is the analytical standard of Xanthosine. This product is intended for research and analytical applications. Xanthosine is a nucleoside derived from xanthine and ribose. Xanthosine activates the *AMPK/FoxO1/AKT/GSK3β* signaling cascade. Xanthosine promotes cell proliferation and regulates blood glucose metabolism. Xanthosine increases milk production in cows and goats. Xanthosine is used in mammary stem cell and type 2 diabetes research .

HY-16558R

Butein (Standard) 2’,3,4,4’-tetrahydroxy Chalcone (Standard)	Reference Standards EGFR Autophagy Apoptosis Phosphodiesterase (PDE)	Cancer
Butein (Standard) is the analytical standard of Butein. This product is intended for research and analytical applications. Butein is a cAMP-specific PDE inhibitor with an IC50 of 10.4 μM for PDE4 . Butein is a specific protein tyrosine kinase inhibitor with IC50s of 16 and 65 μM for EGFR and p60c-src in HepG2 cells . Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a . Butein is a SIRT1 activator (STAC).

HY-N7676

Marein 2 Publications Verification	AMPK HDAC	Cardiovascular Disease Neurological Disease Metabolic Disease
Marein has the neuroprotective effect due to a reduction of damage to mitochondria function and activation of the AMPK signal pathway. Marein improves insulin resistance induced by high glucose in HepG2 cells through CaMKK/AMPK/GLUT1 to promote glucose uptake, through IRS/Akt/GSK-3β to increase glycogen synthesis, and through Akt/FoxO1 to decrease gluconeogenesis. Marein is a HDAC inhibitor with an IC₅₀ of 100 μM. Marein has beneficial antioxidative, antihypertensive, antihyperlipidemic and antidiabetic effects .

HY-116604

RLX PD 139530	PI3K Akt	Cancer
RLX (PD 139530) is a PI3K/Akt/FoxO3a signaling inhibitor, possessing significant therapeutic potential in experimental colon cancer. RLX can effectively modulate the tumor microenvironment, enhancing the efficacy of cancer immunotherapy. RLX demonstrates the ability to improve the retention time of therapeutic agents within the tumor microenvironment by utilizing advanced nanoparticle delivery systems. RLX can be integrated with various treatment modalities, such as chemotherapy and radiotherapy, to enhance overall tumor therapy effectiveness. RLX highlights the necessity for further research into the tumor microenvironment’s dynamics to develop more tailored treatment approaches for diverse tumor types.

HY-W012382

N-Acetyl-L-tyrosine	Endogenous Metabolite	Metabolic Disease Cancer
N-Acetyl-L-tyrosine is an orally active endogenous mitochondrial stress response regulator that can permeate the cell membrane by passive diffusion. N-Acetyl-L-tyrosine induces low-level reactive oxygen species (ROS) generation by transiently perturbing mitochondrial membrane potential, triggering reverse signaling to activate *FoxO* and Keap1 pathways. As a result, N-Acetyl-L-tyrosine enhances the expression of antioxidant enzyme genes, exerting anti-stress and cytoprotective effects. N-Acetyl-L-tyrosine can improve heat stress tolerance, inhibit tumor growth, and regulate energy metabolism. N-Acetyl-L-tyrosine can be used in the research of aging, metabolic diseases (such as diabetes), and cancer .

HY-154919

DC-Y13-27 4 Publications Verification	YTHDF FOXO MMP Pyroptosis Interleukin Related	Endocrinology Cancer
DC-Y13-27 is a DC-Y13 derivative and YTHDF2 inhibitor (K_D: 37.9 μM). DC-Y13-27 inhibits YTHDF2, restores *FOXO3* and TIMP1 protein levels, and reduces MMP1/3/7/9 expression. DC-Y13-27 induces Pyroptosis and increases IL-1β secretion. DC-Y13-27 reduces intervertebral disc degeneration and enhances the response to radiotherapy in colon cancer and melanoma. DC-Y13-27 has antitumor activity against breast cancer .

HY-W012382S

N-Acetyl-L-tyrosine-d3	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease Cancer
N-Acetyl-L-tyrosine-d₃ is the deuterated form of N-Acetyl-L-tyrosine (HY-W012382). N-Acetyl-L-tyrosine is an orally active endogenous mitochondrial stress response regulator that can permeate the cell membrane by passive diffusion. N-Acetyl-L-tyrosine induces low-level reactive oxygen species (ROS) generation by transiently perturbing mitochondrial membrane potential, triggering reverse signaling to activate *FoxO* and Keap1 pathways. As a result, N-Acetyl-L-tyrosine enhances the expression of antioxidant enzyme genes, exerting anti-stress and cytoprotective effects. N-Acetyl-L-tyrosine can improve heat stress tolerance, inhibit tumor growth, and regulate energy metabolism. N-Acetyl-L-tyrosine can be used in the research of aging, metabolic diseases (such as diabetes), and cancer .

HY-W012382R

N-Acetyl-L-tyrosine (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease Cancer
N-Acetyl-L-tyrosine (Standard) is the analytical standard of N-Acetyl-L-tyrosine (HY-W012382). This product is intended for research and analytical applications. N-Acetyl-L-tyrosine is an orally active endogenous mitochondrial stress response regulator that can permeate the cell membrane by passive diffusion. N-Acetyl-L-tyrosine induces low-level reactive oxygen species (ROS) generation by transiently perturbing mitochondrial membrane potential, triggering reverse signaling to activate *FoxO* and Keap1 pathways. As a result, N-Acetyl-L-tyrosine enhances the expression of antioxidant enzyme genes, exerting anti-stress and cytoprotective effects. N-Acetyl-L-tyrosine can improve heat stress tolerance, inhibit tumor growth, and regulate energy metabolism. N-Acetyl-L-tyrosine can be used in the research of aging, metabolic diseases (such as diabetes), and cancer .

HY-N2255

Crebanine 3 Publications Verification	Akt Apoptosis NF-κB Reactive Oxygen Species (ROS) p38 MAPK ERK Interleukin Related TNF Receptor NO Synthase nAChR Bacterial	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Crebanine is an isoquinoline-like alkaloid that can be derived from Stephania. Crebanine is an antagonist of the α7-nAChR with an IC₅₀ of 19.1 μM. Crebanine suppresses the proliferation, migration, and invasion of cancer cells, triggers reactive oxygen species (ROS) burst, and promotes apoptosis. Crebanine inhibits the *AKT/FoxO3a, NF-κB* and MAPK signaling pathways. Crebanine attenuates NOX2 hyperactivation, exhibits antioxidant properties by reducing reactive oxygen species and peroxidation. Crebanine inhibits voltage-dependent Na ⁺ current in guinea-pig ventricular myocytes. Crebanine has high inhibitory activity against gram-positive animal pathogenic bacteria. Crebanine ameliorates ischemia-reperfusion brain damage in middle cerebral artery occlusion and reperfusion (MCAO/R) rats. Crebanine significantly improves Scopolamine (HY-N0296)-induced cognitive deficits in ICR mice. Crebanine can be used for the study of hepatocellular carcinoma (HCC), cerebral ischemia and Alzheimer's disease .

Cat. No.	Product Name	Type

HY-100596G

AS1842856 (GMP)

Fluorescent Dye

AS1842856 (GMP) is AS1842856 (HY-100596) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AS1842856, a specific Foxo1 inhibitor (IC₅₀=30 nM), potently suppresses autophagy . AS1842856 reduces Foxo1 activity and, to a lesser extent, inhibits Foxo1 protein expression by simply binding to Foxo1 .

Cat. No.	Product Name	Type

HY-100596G

AS1842856 (GMP)

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-P4157

FOXO4-DRI	MDM-2/p53 Apoptosis	Metabolic Disease
FOXO4-DRI is a cell-permeable peptide antagonist that blocks the interaction of *FOXO4* and p53. FOXO4-DRI is a senolytic peptide that induces apoptosis of senescent cells .

HY-P4157A

FOXO4-DRI acetate	MDM-2/p53 Apoptosis	Metabolic Disease
FOXO4-DRI acetate is a cell-permeable peptide antagonist that blocks the interaction of *FOXO4* and p53. FOXO4-DRI acetate is a senolytic peptide that induces apoptosis of senescent cells .

HY-P4790

Acetyl-Exenatide	PI3K Akt	Metabolic Disease
Acetyl-Exenatideyes is an acetylated derivative of Exenatide. Exenatide has the function similar to insulin, which can be used for research of type 2 diabetes. Exenatide can promote Th17 differentiation, inhibits Tregs differentiation, downregulates PI3K/Akt/FoxO1 phosphorylation .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N3542

Carpachromene	Structural Classification Flavonoids Flavones Source classification Plants Calophyllaceae Calophyllum symingtonianum M.R.Hend. & Wyatt-Sm.	Glycosidase
Carpachromene is a potent α-glucosidase enzyme inhibitor. Carpachromene ameliorates insulin resistance in HepG2 cells via modulating IR/IRS1/PI3k/Akt/GSK3/FoxO1 pathway .

HY-142125

Broussochalcone A	Structural Classification Chalcones Flavonoids Source classification Plants Moraceae Broussonetia papyrifera (Linnaeus) L'Heritier ex Ventenat	Xanthine Oxidase Reactive Oxygen Species (ROS) Apoptosis
Broussochalcone A is an antioxidant and an inhibitor of Xanthine Oxidase (IC₅₀=2.21 μM), with free radical scavenging activity. Broussochalcone A inhibits iron-induced lipid peroxidation and nitric oxide synthesis in lipopolysaccharide (LPS) -activated macrophages. Broussochalcone A also induces Apoptosis of human renal carcinoma cells by increasing ROS levels and activating FOXO3 signaling pathways .

HY-W011527

Xanthosine 3 Publications Verification	Structural Classification Natural Products Microorganisms Classification of Application Fields Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Xanthosine is a nucleoside derived from xanthine and ribose. Xanthosine activates the *AMPK/FoxO1/AKT/GSK3β* signaling cascade. Xanthosine promotes cell proliferation and regulates blood glucose metabolism. Xanthosine increases milk production in cows and goats. Xanthosine is used in mammary stem cell and type 2 diabetes research .

HY-16558

Butein 5 Publications Verification 2’,3,4,4’-tetrahydroxy Chalcone	Structural Classification Chalcones Flavonoids other families Classification of Application Fields Anti-aging Source classification Phenols Polyphenols Plants Disease Research Fields Cancer	EGFR Autophagy Apoptosis Phosphodiesterase (PDE)
Butein is a cAMP-specific PDE inhibitor with an IC₅₀ of 10.4 μM for PDE4 . Butein is a specific protein tyrosine kinase inhibitor with IC₅₀s of 16 and 65 μM for EGFR and p60 ^c-src in HepG2 cells . Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a . Butein is a SIRT1 activator (STAC).

HY-N7676

Marein 2 Publications Verification	Cardiovascular Disease Structural Classification Chalcones Flavonoids other families Neurological Disease Classification of Application Fields Source classification Phenols Polyphenols Plants Disease Research Fields	AMPK HDAC
Marein has the neuroprotective effect due to a reduction of damage to mitochondria function and activation of the AMPK signal pathway. Marein improves insulin resistance induced by high glucose in HepG2 cells through CaMKK/AMPK/GLUT1 to promote glucose uptake, through IRS/Akt/GSK-3β to increase glycogen synthesis, and through Akt/FoxO1 to decrease gluconeogenesis. Marein is a HDAC inhibitor with an IC₅₀ of 100 μM. Marein has beneficial antioxidative, antihypertensive, antihyperlipidemic and antidiabetic effects .

HY-W012382

N-Acetyl-L-tyrosine	Structural Classification Classification of Application Fields Source classification Endocrine diseases Metabolic Disease Endogenous metabolite Human Gut Microbiota Metabolites Monophenols Microorganisms Ketones, Aldehydes, Acids Disease markers Phenols Disease Research Fields	Endogenous Metabolite
N-Acetyl-L-tyrosine is an orally active endogenous mitochondrial stress response regulator that can permeate the cell membrane by passive diffusion. N-Acetyl-L-tyrosine induces low-level reactive oxygen species (ROS) generation by transiently perturbing mitochondrial membrane potential, triggering reverse signaling to activate *FoxO* and Keap1 pathways. As a result, N-Acetyl-L-tyrosine enhances the expression of antioxidant enzyme genes, exerting anti-stress and cytoprotective effects. N-Acetyl-L-tyrosine can improve heat stress tolerance, inhibit tumor growth, and regulate energy metabolism. N-Acetyl-L-tyrosine can be used in the research of aging, metabolic diseases (such as diabetes), and cancer .

HY-W012382R

N-Acetyl-L-tyrosine (Standard)	Structural Classification Human Gut Microbiota Metabolites Monophenols Microorganisms Ketones, Aldehydes, Acids Source classification Disease markers Phenols Endocrine diseases Endogenous metabolite	Reference Standards Endogenous Metabolite
N-Acetyl-L-tyrosine (Standard) is the analytical standard of N-Acetyl-L-tyrosine (HY-W012382). This product is intended for research and analytical applications. N-Acetyl-L-tyrosine is an orally active endogenous mitochondrial stress response regulator that can permeate the cell membrane by passive diffusion. N-Acetyl-L-tyrosine induces low-level reactive oxygen species (ROS) generation by transiently perturbing mitochondrial membrane potential, triggering reverse signaling to activate *FoxO* and Keap1 pathways. As a result, N-Acetyl-L-tyrosine enhances the expression of antioxidant enzyme genes, exerting anti-stress and cytoprotective effects. N-Acetyl-L-tyrosine can improve heat stress tolerance, inhibit tumor growth, and regulate energy metabolism. N-Acetyl-L-tyrosine can be used in the research of aging, metabolic diseases (such as diabetes), and cancer .

HY-122959

Kihadanin B	Other Terpenoids Structural Classification Terpenoids Dictamnus dasycarpus Turcz. Source classification Rutaceae Plants	Akt PPAR
Kihadanin B is a citrus limonoid that can be purified from the peels of immature Citrus unshiu. Kihadanin B suppresses adipogenesis through repression of the *Akt-FOXO1-PPARγ* axis in 3T3-L1 adipocytes .

HY-W011527R

Xanthosine (Standard)	Structural Classification Natural Products Microorganisms Source classification Endogenous metabolite	Reference Standards Endogenous Metabolite
Xanthosine (Standard) is the analytical standard of Xanthosine. This product is intended for research and analytical applications. Xanthosine is a nucleoside derived from xanthine and ribose. Xanthosine activates the *AMPK/FoxO1/AKT/GSK3β* signaling cascade. Xanthosine promotes cell proliferation and regulates blood glucose metabolism. Xanthosine increases milk production in cows and goats. Xanthosine is used in mammary stem cell and type 2 diabetes research .

HY-16558R

Butein (Standard) 2’,3,4,4’-tetrahydroxy Chalcone (Standard)	Structural Classification Chalcones Flavonoids other families Source classification Phenols Polyphenols Plants	Reference Standards EGFR Autophagy Apoptosis Phosphodiesterase (PDE)
Butein (Standard) is the analytical standard of Butein. This product is intended for research and analytical applications. Butein is a cAMP-specific PDE inhibitor with an IC50 of 10.4 μM for PDE4 . Butein is a specific protein tyrosine kinase inhibitor with IC50s of 16 and 65 μM for EGFR and p60c-src in HepG2 cells . Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a . Butein is a SIRT1 activator (STAC).

HY-N2255

Crebanine 3 Publications Verification	Cardiovascular Disease Structural Classification Alkaloids Stephania venosa Classification of Application Fields Other Alkaloids Plants Menispermaceae Inflammation/Immunology Disease Research Fields	Akt Apoptosis NF-κB Reactive Oxygen Species (ROS) p38 MAPK ERK Interleukin Related TNF Receptor NO Synthase nAChR Bacterial
Crebanine is an isoquinoline-like alkaloid that can be derived from Stephania. Crebanine is an antagonist of the α7-nAChR with an IC₅₀ of 19.1 μM. Crebanine suppresses the proliferation, migration, and invasion of cancer cells, triggers reactive oxygen species (ROS) burst, and promotes apoptosis. Crebanine inhibits the *AKT/FoxO3a, NF-κB* and MAPK signaling pathways. Crebanine attenuates NOX2 hyperactivation, exhibits antioxidant properties by reducing reactive oxygen species and peroxidation. Crebanine inhibits voltage-dependent Na ⁺ current in guinea-pig ventricular myocytes. Crebanine has high inhibitory activity against gram-positive animal pathogenic bacteria. Crebanine ameliorates ischemia-reperfusion brain damage in middle cerebral artery occlusion and reperfusion (MCAO/R) rats. Crebanine significantly improves Scopolamine (HY-N0296)-induced cognitive deficits in ICR mice. Crebanine can be used for the study of hepatocellular carcinoma (HCC), cerebral ischemia and Alzheimer's disease .

Cat. No.	Compare	Product Name	Species	Source

HY-P701170

	FOXO3 Protein, Human (HEK293, His) AF6q21; FKHRL1; FKHRL1P2; FOXO2; FOXO3A	Human	HEK293
	The FOXO3 protein is a multifaceted transcriptional activator that regulates apoptosis, autophagy, and post-transcriptional MYC control. It actively regulates autophagy in skeletal muscle and induces autophagy gene expression under starvation conditions. FOXO3 Protein, Human (HEK293, His) is the recombinant human-derived FOXO3 protein, expressed by HEK293 , with C-10*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-W012382S

N-Acetyl-L-tyrosine-d3

N-Acetyl-L-tyrosine-d₃ is the deuterated form of N-Acetyl-L-tyrosine (HY-W012382). N-Acetyl-L-tyrosine is an orally active endogenous mitochondrial stress response regulator that can permeate the cell membrane by passive diffusion. N-Acetyl-L-tyrosine induces low-level reactive oxygen species (ROS) generation by transiently perturbing mitochondrial membrane potential, triggering reverse signaling to activate FoxO and Keap1 pathways. As a result, N-Acetyl-L-tyrosine enhances the expression of antioxidant enzyme genes, exerting anti-stress and cytoprotective effects. N-Acetyl-L-tyrosine can improve heat stress tolerance, inhibit tumor growth, and regulate energy metabolism. N-Acetyl-L-tyrosine can be used in the research of aging, metabolic diseases (such as diabetes), and cancer .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81074

	FOXO1/FOXO1A Antibody FOXO1; FKHR; FOXO1A; Forkhead box protein O1; Forkhead box protein O1A; Forkhead in rhabdomyosarcoma	WB, IHC-F, IHC-P, ICC/IF, ELISA, ChIP	Human, Mouse, Rat, Pig
	FOXO1/FOXO1A Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to FOXO1/FOXO1A.

HY-P80676

	FOXO1/FOXO1A Antibody (YA430) FOXO1; FKHR; FOXO1A; Forkhead box protein O1; Forkhead box protein O1A; Forkhead in rhabdomyosarcoma	WB, IHC-F, IHC-P, ICC/IF	Human
	FOXO1/FOXO1A Antibody (YA430) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to FOXO1/FOXO1A.

HY-P80134

	FOXO4 Antibody (YA426)	WB, ICC/IF, IHC-P, FC, IP	Human
	FOXO4 Antibody (YA426) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to FOXO4.

HY-P80132

	FOXO1A Antibody (YA429)	WB, ICC/IF, IHC-P	Human, Mouse
	FOXO1A Antibody (YA429) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to FOXO1A.

HY-P80677

	FOXO3A Antibody (YA428) FOXO3; FKHRL1; FOXO3A; Forkhead box protein O3; AF6q21 protein; Forkhead in rhabdomyosarcoma-like 1	WB	Human
	FOXO3A Antibody (YA428) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to FOXO3A.

HY-P80817

	*Phospho-FOXO3A (Ser253) Antibody (YA197)* FOXO3; FKHRL1; FOXO3A; Forkhead box protein O3; AF6q21 protein; Forkhead in rhabdomyosarcoma-like 1	WB	Human, Mouse, Rat
	Phospho-FOXO3A (Ser253) Antibody (YA197) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-FOXO3A (Ser253).

HY-P85429

	FoxO1 Antibody (YA5121) FOXO1; FKHR; FOXO1A; Forkhead box protein O1; Forkhead box protein O1A; Forkhead in rhabdomyosarcoma	WB, ICC/IF	Human, Mouse
	FoxO1 Antibody (YA5121) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to FoxO1.

HY-P86588

	FOXO1 Antibody (YA6280) FOXO1; FKHR; FOXO1A; Forkhead box protein O1; Forkhead box protein O1A; Forkhead in rhabdomyosarcoma	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse,
	FOXO1 Antibody (YA6280) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to FOXO1.

HY-P85525

	FOXO1(C-term) Antibody (YA5217) FKH 1; FKH1; FKH1; FKHR; FKHR; Forkhead; Drosophila; homolog 1; rhabdomyosarcoma; Forkhead; Drosophila; homolog 1; rhabdomyosarcoma; Forkhead box O1; Forkhead box protein O1; Forkhead box protein O1A; Forkhead in rhabdomyosarcoma; Forkhead, Drosophila, homolog of, in rhabdomyosarcoma; FOXO1; FOXO1; FOXO1_HUMAN; FOXO1A; OTTHUMP00000018301.	WB	Human
	FOXO1(C-term) Antibody (YA5217) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to FOXO1(C-term).

HY-P86548

	*Phospho-FOXO3A(Ser253) Antibody (YA6240)* FOXO3; FKHRL1; FOXO3A; Forkhead box protein O3; AF6q21 protein; Forkhead in rhabdomyosarcoma-like 1	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Phospho-FOXO3A(Ser253) Antibody (YA6240) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-FOXO3A(Ser253).

HY-P80461

	*Phospho-FOXO3A(Ser253) Antibody (YA196)*	WB, IHC-P	Human, Mouse, Rat
	Phospho-FOXO3A(Ser253) Antibody (YA196) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-FOXO3A(Ser253).

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

FOXO

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Natural
Products